Imunon (CLSN) Stock Price, News & Analysis

Company Overview

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.95 to $2.63
• 52-Week Range: N/A
• Volume: 711 shs
• Average Volume: 150,471 shs
• Market Capitalization: $13.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CLSN Stock Analysis - Frequently Asked Questions

How were Imunon's earnings last quarter?

Imunon, Inc. (NASDAQ:CLSN) issued its quarterly earnings data on Monday, August, 15th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.25. Imunon had a negative net margin of 5,229.80% and a negative trailing twelve-month return on equity of 50.18%.

When did Imunon's stock split?

Imunon's stock reverse split before market open on Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Imunon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Acasti Pharma (ACST), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

Company Calendar

• Last Earnings: 8/15/2022
• Today: 11/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CLSN
• CUSIP: N/A
• CIK: 749647
• Web: www.celsion.com
• Phone: (609) 896-9100
• Fax: 609-896-2200
• Employees: 27
• Year Founded: 1982

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,770,000.00
• Net Margins: -5,229.80%
• Pretax Margin: -5,506.60%
• Return on Equity: -50.18%
• Return on Assets: -36.94%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 6.52
• Quick Ratio: 6.52

Sales & Book Value

• Annual Sales: $500,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.66 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 7,099,000
• Free Float: 6,768,000
• Market Cap: $13.91 million
• Optionable: Optionable
• Beta: 2.27